ArQule, Inc. (NASDAQ:ARQL) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 4, 2016
Having a price of $1.71, ArQule, Inc. (NASDAQ:ARQL) traded -6.04% lower on the day. With the last close up 4.37% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ARQL has recorded a 50-day average of $1.54 and a two hundred day average of $1.64. Trade Volume was down over the average, with 62,170 shares of ARQL changing hands under the typical 92,250
Zacks Investment Research has downgraded ArQule, Inc. (NASDAQ:ARQL) to Hold in a statement released on 10/04/2016.
Recent Performance Chart
ArQule, Inc. has with a one year low of $1.37 and a one year high of $2.65 and has a market capitalization of $0.
General Company Details For ArQule, Inc. (NASDAQ:ARQL)
ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.